Leker Ronen R
Laboratory of Molecular Biology, NIH/NINDS Building 36, Room 3c12, 36 Convent Drive, MSC 4092, Bethesda, MD 20892, USA.
Curr Opin Investig Drugs. 2003 Jan;4(1):83-90.
Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.
